The bisphosphonate zoledronic acid effectively targets lung cancer cells by inhibition of protein prenylation

Xie, Fan; Li, Pengcheng; Gong, Jianhua; Zhang, Jiahong; Ma, Jin

doi:10.1016/j.bbrc.2015.10.089

Cited by 14 publications

(10 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…BP acts by inhibiting protein prenylation in the lung cancer cells as shown by the increased levels of unprenylated Ras and Rap1A. This leads to the inhibitory effect on the proliferation and viability of the cells (Xie, Li, Gong, Zhang, & Ma, 2015).…”

Section: Discussionmentioning

confidence: 99%

Alteration of macrophage viability, differentiation, and function by bisphosphonates

Patntirapong

Poolgesorn

2018

Oral Diseases

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Alteration of macrophage viability, differentiation, and function by bisphosphonates

Patntirapong

Poolgesorn

2018

Oral Diseases

View full text Add to dashboard Cite

show abstract

“…Preclinical studies have shown that bisphosphonates can induce apoptosis, and inhibit cell invasion and tumor angiogenesis [ 30 , 32 , 33 ] through their activation of gamma delta T cells, induction cytokines production, and contribution to immune response to tumor cells [ 31 , 34 , 35 ]. In vitro studies showed that zoledronic acid, a third generation bisphosphonate, inhibits the prenylation of small G-proteins such as Ras, reduces the signals and prevents the growth of lung cancer cells [ 36 , 37 ]. In vivo studies also revealed that bisphosphonates show the antitumor and antiangiogenic effects through their ability to inhibit tumor cell growth and vascular endothelial growth factor release in NSCLC cell lines [ 38 , 39 ].…”

Section: Discussionmentioning

confidence: 99%

“…In vivo studies also revealed that bisphosphonates show the antitumor and antiangiogenic effects through their ability to inhibit tumor cell growth and vascular endothelial growth factor release in NSCLC cell lines [ 38 , 39 ]. Furthermore, bisphosphonates were shown to inactive human epidermal growth factor receptors (EGFRs) in both NSCLC cell lines and in mice with NSCLC [ 36 , 40 , 41 ]. The EGFR pathway is particularly relevant to progression of lung adenocarcinoma [ 42 ].…”

Section: Discussionmentioning

confidence: 99%

Oral bisphosphonate use and lung cancer incidence among postmenopausal women

et al. 2018

View full text Add to dashboard Cite

BackgroundBisphosphonates are common medications for the treatment of osteoporosis in older populations. Several studies, including the Women’s Health Initiative (WHI), have found inverse associations of bisphosphonate use with risk of breast and endometrial cancer, but little is known about its association with other common malignancies. The objective of this study was to evaluate the association of bisphosphonate use on the incidence of lung cancer in the WHI.Patients and methodsThe association between oral bisphosphonate use and lung cancer risk was examined in 151 432 postmenopausal women enrolled into the WHI in 1993–1998. At baseline and during follow-up, participants completed an inventory of regularly used medications including bisphosphonates.ResultsAfter a mean follow-up of 13.3 years, 2511 women were diagnosed with incident lung cancer. There was no evidence of a difference in lung cancer incidence between oral bisphosphonate users and never users (adjusted hazard ratio = 0.91; 95% confidence intervals, 0.80–1.04; P = 0.16). However, an inverse association was observed among those who were never smokers (hazard ratio = 0.57, 95% confidence interval, 0.39–0.84; P < 0.01).ConclusionIn this large prospective cohort of postmenopausal women, oral bisphosphonate use was associated with significantly lower lung cancer risk among never smokers, suggesting bisphosphonates may have a protective effect against lung cancer. Additional studies are needed to confirm our findings.

show abstract

“…It has been suggested ( 16 ) that zoledronic acid can be used in the treatment of NSCLC to prevent or delay the occurrence of bone-related events. Previous findings have shown that, the therapeutic effect of zoledronic acid on lung cancer is achieved by inhibiting protein prenylation ( 17 ). Silva et al ( 18 ) indicated in their study that zoledronic acid could alter bone microenvironment and affect the growth of bone and bone tumors, so as to effectively reduce the risk of bone-related events.…”

Section: Discussionmentioning

confidence: 99%

Effects of zoledronic acid and ibandronate in the treatment of cancer pain in rats with lung cancer combined with bone metastases

Wang

Chen

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

The aim of the study was to investigate the efficiency and safety of zoledronic acid and ibandronate in the treatment of rats with lung cancer combined with bone metastases. A total of 124 rats with lung cancer bone metastasis were established. Rats were randomly divided into A, B and C groups (n=30). Rats in group A were treated with ibandronate combined with zoledronic acid, rats in group B were treated with zoledronic acid monotherapy, and rats in group C were treated with ibandronate monotherapy. Rats in group A were injected subcutaneously with zoledronic acid 0.1 mg/kg and ibandronate 10 µg/kg, once per week for 12 weeks; rats in group B were injected subcutaneously with zoledronic acid, and rats in group C were injected subcutaneously with ibandronate, the same method as the treatment group. The remaining 34 SD rats were not treated to serve as the control group. Treatment efficacy and physical improvement in 8 weeks were observed, and improvement of pain behavior in rats was evaluated to reflect the effect of drug treatment. Of the 30 rats in group A, 25 showed different degrees of remission, 5 rats showed no improvement and the effective rate was 83.3%. Of the 30 rats in group B, 21 showed different degrees of remission, 9 rats showed no improvement and the effective rate was 70%. Of the 30 rats in group C, 20 showed different degrees of remission, 10 rats showed no improvement and the effective rate was 66.7%. Statistically significant differences in total effective rate were found among three groups, and the combined method showed the highest effective rate (P<0.05). Ibandronate combined with zoledronic acid has a good therapeutic effect on cancer pain caused by bone metastases from lung cancer.

show abstract

The bisphosphonate zoledronic acid effectively targets lung cancer cells by inhibition of protein prenylation

Cited by 14 publications

References 20 publications

Alteration of macrophage viability, differentiation, and function by bisphosphonates

Alteration of macrophage viability, differentiation, and function by bisphosphonates

Oral bisphosphonate use and lung cancer incidence among postmenopausal women

Effects of zoledronic acid and ibandronate in the treatment of cancer pain in rats with lung cancer combined with bone metastases

Contact Info

Product

Resources

About